Recently, a series of bis-indole-derived analogs (CDIMs) that bind to the LBD of NR4A1 and act as NR4A1 antagonists have been developed, and treatment with several CDIMs have been shown to inhibit the NR4A1-regulated pro-oncogenic responses in multiple cancer cells including pancreatic cancer [4]. This evidence concerns the gene NR4A1 and familial pancreatic carcinoma.